Why the study?
Despite increasing clinical adoption, percutaneous LAAO requires further optimization regarding safety and efficacy data, standardized pre-procedural planning, and procedural simplification when compared with newer oral anticoagulants.
This review highlights future opportunities for enhancing the safety and efficacy of percutaneous left atrial appendage occlusion to establish it as a mainstream strategy for stroke prevention in patients with atrial fibrillation contraindicated for anticoagulants.
Answers are grounded in this paper and cite their sources.
May prompt targeted LAAO refinements; leaves open mainstream adoption without new randomized data.
Percutaneous left atrial appendage occlusion (LAAO), currently recognized as a procedure with relatively low risk, is increasingly being adopted in clinical practice. However, due to the preventive nature of the procedure and the necessity to compare it with newer and safer oral anticoagulants, further optimization is required to address remaining challenges. These latter include acquiring comprehensive data on safety and efficacy, establishing standardized pre-procedural planning, and simplifying procedural process. Consequently, we have provided an overview that encompasses future opportunities for enhancing procedural safety and efficacy, thereby establishing LAAO as the mainstream strategy for stroke and systemic embolism prevention in patients with atrial fibrillation and absolute contraindications to anticoagulant drugs.
No takes yet. Share an insight, caveat, or question.
Casenghi et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: